The ERA-Net “Cofund on BioTechnologies” (ERA CoBioTech) aims to better use synergies between current mechanisms of biotechnology research funding in Europe, to highlight the benefits of a bio-based economy for society, and to thus maintain and strengthen Europe’s global lead in modern biotechnology. The co-funded call will focus on application-oriented research in: a) Synthetic biology approaches to design and construct new biological parts, devices and systems b) Systems biology approaches to metabolic engineering and optimisation of biological processes c) Identification and use of the metabolic potentials of genomic data d) Chemical and biotechnological approaches to transform bio-based molecules into molecules with high added value. Bundling three predecessor ERA-Nets in the area of biotechnology, ERA CoBioTech significantly increases public funding (call volume ~ 30 Mio €), intensifies collaboration across relevant sectors and countries, and thus - advances RD&I in industrial biotechnology - establishes systems and synthetic biology as technology drivers in applied biotechnology, and - enhances the potential for exploitation through active industry involvement. Necessary steps and measures to achieve these goals will be encompassed in a joint Strategic Agenda. With a “European Biotechnology Hub”, ERA CoBioTech realises an entirely new concept, reaching out to key actors and stakeholders from multiple biotechnology-related areas in order to align different European strategic instruments with the goals of the KET biotechnology programme under Horizon 2020 and to increase public awareness of biotechnology for industrial uses. ERA CoBioTech will implement additional funding activities without EC co-funding, which will advance RD&I in industrial biotechnology in line with the Strategic Agenda and the outcomes of the "European Biotechnology Hub." ERA CoBioTech thus provides biotechnology stakeholders with tailor-made support regarding information, communication, networking and funding.

Cardiovascular diseases (CVD) are the largest cause of death in the EU and account for around 2 million deaths per year. Overall, CVD are estimated to cause the economy of the EU costs of almost 196 billion Euros a year. Furthermore, they are one of the leading causes of long term sickness, chronic diseases and loss to the labour market. Therefore, CVD are a major health problem in Europe. Despite the overall burden of CVD on European citizens and national health systems, translational cardiovascular research is fragmented and mainly occurs at national levels. However, the present and future challenges in cardiovascular research can only be met by an effective cooperation at transnational level. Therefore, the proposed European Research Area Network on cardiovascular diseases (ERA-CVD) aims to coordinate national and regional programmes for translational research in the area CVD by implementing one Joint Transnational Call (JTC2016) with EU Co-funding followed by further non-co-funded JTC (2017-2019). Although this consortium will be newly established, a collaboration and alignment of national programmes and activities has already been achieved during the preparation of the ERA-Net Co-fund proposal. This process is supported by CardioScape an EU-funded survey of the European cardiovascular research landscape coordinated by the European Society of Cardiology (ESC). The current ERA-CVD proposal will extend and strengthen the transnational cooperation of the current 23 ministries/institutions/foundations from 18 European, associated and third countries. Furthermore, ERA-CVD plans to cooperate with the ESC and the European Heart Network (EHN). Moreover, the collaboration with European Research Infrastructures, e.g. the ESFRI-initiatives is intended in order to set up an efficient European framework for innovative transnational research on CVD. Also the extension of the consortium and international collaborations are intended.